Resources

Prove ADCC Activity in Real Human Skin For therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential. Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platformRead more

Genoskin raises $8.7M series Ato support drug development with ethical, human-based modelsFunding to accelerate global expansion and strengthen scientific leadership We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhanceRead more

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Top-level science through the eyes of an expert.Join us for the next session of Naked Immunology Webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. In this session we will discuss how the immune system’s reaction to neuromuscular blockers could offer new therapeutic insights. WATCH NOWThis webinar explores new insights into the antibody responses of patientsRead more

NativeSkin® & PharmaApplication NoteNativeSkin®: a human skin model for pharma applications Discover NativeSkin®, an advanced ex vivo human skin model designed to provide a physiologically relevant, cruelty-free platform for pharmaceutical research. This patented model preserves the structure, cellular complexity, and barrier function of real human skin, enabling reliable assessments of drug efficacy (e.g., transdermal delivery, topical activity, anti-inflammatory effects) andRead more

Vaccine DevelopmentVaxSkin® an innovative platform to study vaccine immunogenicityIntroduction The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. Developing safe and effective vaccines requires a clear understanding of early immune responses at the injectionRead more